Media.Player

Neuropeptide S (NPS) as a Treatment for Anxiety, Sleep Disorders, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, and Asthma

Technology Application

The NPS receptor may be used as a system to assay for agonists that are useful therapeutic agents in narcolepsy, hypersomnia or under conditions when elevated alertness is required. Antagonists to the NPS receptor may also be assayed for novel therapeutic approach to treat insomnia. NPS may also be used in the treatment or prevention of asthma and it also may be used as a therapeutic in Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Disorder (ADD).

Detailed Technology Description

University of California, Irvine researchers have shown that central administration of NPS increases locomotor activity in mice and decreases paradoxical (REM) sleep and slow wave sleep in rats. NPS was further shown to produce anxiolytic-like effects in mice exposed to different stressful paradigms.

Supplementary Information

Patent Number: US20100056455A1
Application Number: US2006587444A
Inventor: Civelli, Olivier | Reinscheld, Rainer K | Xu, Yanling
Priority Date: 23 Apr 2004
Priority Number: US20100056455A1
Application Date: 9 Sep 2009
Publication Date: 4 Mar 2010
IPC Current: A61K003817 | A61P002500 | C07K0014435
US Class: 5140126 | 514013 | 530326
Title: Therapies Which Act on Neuropeptide S Receptors
Usefulness: Therapies Which Act on Neuropeptide S Receptors
Summary: (I) is useful to cause arousal, awakening, alertness, spontaneous movement, anxiolytic effects, bronchoconstriction and contraction of bronchial smooth muscle in a human or animal subject. The method of administering (I) is useful to treat a disorder (narcolepsy, hypersomnia, lack of alertness, lack of attentiveness, absentmindedness and lack of or aversion to movement or exercise, anxiety, stress or stress related disorders). The method of administering (II) is useful to treat a disorder (insomnia, sleep disorders, decreased sleep duration, frequent awakening, disorders that cause excessive spontaneous movement, behavioral disorders, bronchitis, obstructive pulmonary disease, asthma and allergic conditions). (I) and (II) are useful in the manufacture of a preparation that is used to carry out the methods (all claimed). The effect of (I) on locomotor activity was tested in mice. The results showed that (I) significantly increased the locomotor activity.
Novelty: Use of neuropeptide S receptor agonist to cause arousal, awakening, alertness, spontaneous movement, anxiolytic effects, bronchoconstriction and contraction of bronchial smooth muscle

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

9012407

Others

Tech ID/UC Case

18857/2004-053-0

Related Cases

2004-053-0

*Abstract

Patent "WO02/31145" discloses a newly deorphanized GPCR system, Neuropeptide S (NPS), the endogenous ligand, and its cognate GPCR. However this patent does not detail the pharmacological or physiological function of NPS and its GPCR. University of California, Irvine researchers have characterized NPS's function in the CNS.

*IP Issue Date

Apr 21, 2015

*Principal Investigator

Name: Olivier Civelli

Department:

Name: Rainer Reinscheid

Department:

Name: Yanling Xu

Department:

Country/Region

USA